Analysis of nuclear sugar-binding components in undifferentiated and in vitro differentiated human promyelocytic leukemia cells (HL60).
The nuclear sugar-binding components (i.e., lectin-like molecules) were analyzed using isolated and membrane-depleted nuclei after incubation in the presence of fluorescein-labeled neoglycoproteins. This analysis was performed before and during the in vitro differentiation of HL60 cells into monocytes by PMA treatment and into granulocytes by DMSO treatment. The nucleoli of undifferentiated and differentiated HL60 cells were not labeled, unlike the nucleoli of other mammalian cells studied so far. This peculiarity allowed us to quantitatively analyze by flow cytometry the changes in the lectin activity associated with the extranucleolar territories enriched in ribonucleoprotein complexes. The neoglycoprotein binding was found to be significantly lower in differentiated than in undifferentiated cells. The decrease in neoglycoprotein binding was observed within the first 24 h of DMSO or PMA treatment, just before the arrest of DNA synthesis. Taking into account that the granulocytic differentiation required 72 h of chemical treatment, the extra-nucleolar lectins might be involved in modulation of the DNA synthesis rather than in phenotypic differentiation. These data are discussed in an attempt to reconcile the association of lectins with RNP complexes and their possible involvement in modulation of HL60 cell proliferation.
Facy
P
P
CNRS, Département de Biochimie des Glycoconjugués et Lectines Endogènes, Orléans, France.
Seve
A P
AP
Hubert
M
M
Monsigny
M
M
Hubert
J
J
D002352:Carrier Proteins / Q000032:analysis* / Q000378:metabolism / Q000502:physiology; D002454:Cell Differentiation / Q000502:physiology; D002467:Cell Nucleus / Q000737:chemistry / Q000187:drug effects / Q000648:ultrastructure; D002471:Cell Transformation, Neoplastic / Q000737:chemistry / Q000187:drug effects / Q000473:pathology*; D004247:DNA / Q000032:analysis / Q000096:biosynthesis; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D019793:Fluorescein; D005452:Fluoresceins; D006801:Humans; D037102:Lectins / Q000032:analysis / Q000378:metabolism / Q000502:physiology; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism / Q000473:pathology*; D008856:Microscopy, Fluorescence; D009687:Nuclear Proteins / Q000032:analysis* / Q000378:metabolism / Q000502:physiology; D010641:Phenotype; D011956:Receptors, Cell Surface; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D002352:Carrier Proteins; D005452:Fluoresceins; D037102:Lectins; D009687:Nuclear Proteins; D011956:Receptors, Cell Surface; C055213:saccharide-binding proteins; D004247:DNA; D013755:Tetradecanoylphorbol Acetate; D019793:Fluorescein; D004121:Dimethyl Sulfoxide